Chugai Announced New Mid-Term “Sunrise 2012” Plan
This article was originally published in PharmAsia News
Chugai President Naoru Nagayama announced a new mid-term business plan, Sunrise 2012, at a Jan. 30 briefing to stave off a lowered profit target from ¥100 billion to ¥80 billion. He said he is still optimistic about maximum value generation from the company's new products, and that its alliance with Roche has reinforced its cancer drug pipeline. In 2007, three new products - Avastin, Tarceva and Copegus went on sale. Chugai's IL-6 receptor antibody Actemra also was submitted for approval overseas. Nagayama said these developments indicated the portfolio is bearing fruit. Chugai will also strengthen marketing and sales operations, and will set up a portfolio management committee and strategic marketing committee, aiming to defend market shares for current products and realize maximum valuation for new cancer treatments. (Click for more-Japanese language
You may also be interested in...
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.